FerdinandosSkoulidisMD

Physician

Dr. Skoulidis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

PubMed

Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary.
Adrianus Johannes de Langen, Melissa L Johnson, Julien Mazieres, Anne-Marie C Dingemans, Giannis Mountzios
Future Oncology. 2025-03-24
Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial.
Marcelo V Negrao, Alvaro G Paula, David Molkentine, Laura Hover, Monique Nilsson
Clinical Cancer Research. 2025-03-17
1 citations
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun
Nature. 2025-03-01

Lectures

Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell l...
2019 ASCO Annual Meeting - 6/1/2019
Association of STK11/LKB1 mutations with primary resistance to PD-1/PD-L1 axis blockade in PD-L1 positive non-squamous NSCLC.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Should First-Line Dual Checkpoint Blockade Be Used for NSCLC with Specific Mutations?October 24th, 2024
Dual Immunotherapy plus Chemotherapy Benefits Specific Subset of Patients with Lung CancerOctober 9th, 2024
MD Anderson Research Highlights for July 11, 2024July 11th, 2024
Join now to see all

Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitorUNIVERSITY OF TX MD ANDERSON CAN CTR2023–2028
Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitorUNIVERSITY OF TX MD ANDERSON CAN CTR2023–2028
Dissecting and targeting tumor-TME crosstalk to forestall acquired KRASG12C inhibitor resistance in NSCLC.UNIVERSITY OF TX MD ANDERSON CAN CTR2023–2028
Dissecting and targeting mechanisms of genomic instability-triggered immune evasion in RBM10-deficient non-small cell lung cancerUNIVERSITY OF TX MD ANDERSON CAN CTR2023–2028
Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitorUNIVERSITY OF TX MD ANDERSON CAN CTR2023–2028
Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancerUNIVERSITY OF TX MD ANDERSON CAN CTR2021–2026
Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancerUNIVERSITY OF TX MD ANDERSON CAN CTR2021–2026
Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancerUNIVERSITY OF TX MD ANDERSON CAN CTR2021–2026